A Clinical Trial of CSL's 2010/2011 Formulation of Enzira® in a Healthy Adult Population

A Phase IV, Single-centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2010/2011 Formulation of Enzira® Vaccine in Two Groups of Healthy Volunteers: 'Adults' (Aged 18 to 59 Years) and 'Older Adults' (Aged 60 Years or Older)

The purpose of this study is to determine whether the 2010/2011 Formulation Enzira vaccine is safe and elicits an immune response to seasonal influenza in healthy adults.

Inclusion Criteria:

• Male or female aged 18 years and older at the time of the first study vaccination.

Exclusion Criteria:

• Known hypersensitivity to a previous dose of influenza virus vaccine or allergy to eggs, chicken protein, neomycin, polymyxin, or any components of the Study Vaccine.
• Clinical signs of an active infection
• Vaccination with a seasonal or experimental influenza virus vaccine in the 6 months preceding study entry
• Females who are pregnant or lactating